Albert Yu, M.D.
Chief Medical Officer
Dr. Albert Yu joined Petra after being an independent consultant since 2014. He has 25 years of drug development experience across multiple therapeutic areas. He has introduced over a dozen new drug candidates into clinical development and was a key contributor to the development of two marketed drugs: Cialis® for the treatment of patients with erectile dysfunction and Zydelig® for the treatment of patients with chronic lymphocytic leukemia and follicular lymphoma.
Previously he was the Vice President of Clinical Development at Omeros Corporation, the Chief Medical Officer at Calistoga Pharmaceuticals, Inc. and the Senior Director of Clinical Affairs at ICOS Corporation.
Dr. Yu is trained in Internal Medicine and Pulmonary and Critical Care Medicine and is a graduate of University of Washington School of Medicine and Massachusetts Institute of Technology. He also serves on the Scientific Advisory Board of OncoResponse, Inc.